SEC Tracker
Get the app

Geron GERN

Geron reports $1.35 million net income for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $60.19 million for the three months ended Sep 30, 2026
  2. Net income of $1.35 million for the three months ended Sep 30, 2026
  3. Cash and equivalents of $69.18 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Geron files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
  2. Wave Life Sciences WVE public float $851M, Jun 30, 2025
  3. CorMedix CRMD public float $910M, Jun 30, 2025
  4. Niagen Bioscience NAGE public float $814M, Jun 30, 2025
  5. Nurix Therapeutics NRIX public float $808M, May 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.